You are here

  • Home
  • Archive
  • Volume 3, Issue 7
  • Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol

Article Text

Article menu

Download PDFPDF

XML
Obstetrics and gynaecology
Protocol
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol
  1. Andrew W Horne1,
  2. Monika M Skubisz2,
  3. Ann Doust1,
  4. W Colin Duncan1,
  5. Euan Wallace3,
  6. Hilary O D Critchley1,
  7. Terrance G Johns3,
  8. Jane E Norman1,
  9. Siladitya Bhattacharya4,
  10. Jill Mollison4,
  11. Michael Rassmusen5,
  12. Stephen Tong2
  1. 1MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
  2. 2Translational Obstetrics Group, University of Melbourne, Mercy Hospital for Women, Melbourne, Australia
  3. 3Monash Institute of Medical Research, Clayton, Australia
  4. 4Obstetrics and Gynaecology, Division of Applied Clinical Sciences, University of Aberdeen, Aberdeen Maternity Hospital, Aberdeen, UK
  5. 5Mercy Hospital for Women, Melbourne, Australia
  1. Correspondence to Dr Andrew Horne; andrew.horne{at}ed.ac.uk

Abstract

Introduction Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. tEPs with pretreatment serum human chorionic gonadotrophin (hCG) levels <1000 IU/L respond well to outpatient medical treatment with intramuscular methotrexate (MTX). TEPs with hCG >1000 IU/L take a significant time to resolve with MTX and require multiple outpatient monitoring visits. Gefitinib is an orally active epidermal growth factor receptor (EGFR) antagonist. In preclinical studies, we found that EP implantation sites express high levels of EGFR and that gefitinib augments MTX-induced regression of pregnancy-like tissue. We performed a phase I toxicity study administering oral gefitinib and intramuscular MTX to 12 women with tEPs. The combination therapy did not cause significant toxicities and was well tolerated. We noted that combination therapy resolved the tEPs faster than MTX alone. We now describe the protocol of a larger single arm trial to estimate the efficacy and side effects of combination gefitinib and MTX to treat stable tEPs with hCG 1000–10 000 IU/L

Methods and analysis We propose to undertake a single-arm multicentre open label trial (in Edinburgh and Melbourne) and recruit 28 women with tEPs (pretreatment serum hCG 1000–10 000 IU/L). We intend to give a single dose of intramuscular MTX (50 mg/m2) and oral gefitinib (250 mg) daily for 7 days. Our primary outcome is the resolution of EP to non-pregnant hCG levels <15 IU/L without requirement of surgery. Our secondary outcomes are comparison of time to resolution against historical controls given MTX only, and safety and tolerability as determined by clinical/biochemical assessment.

Ethics and dissemination Ethical approval has been obtained from Scotland A Research Ethics Committee (MREC 11/AL/0350), Southern Health Human Research Ethics Committee B (HREC 11180B) and the Mercy Health Human Research Ethics Committee (R12/25). Data will be presented at international conferences and published in peer-reviewed journals.

Trial registration number ACTRN12611001056987.

  • Reproductive Medicine
  • Gynaecology

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/

https://doi.org/10.1136/bmjopen-2013-002902

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Article summary

    Article focus

    • Protocol of a study to determine:

    • Is combination therapy with MTX and gefitinib effective at resolving tEP?

    • Is combination therapy with MTX and gefitinib safe and well tolerated?

    Key messages

    • Tubal ectopic pregnancy (tEPs) with hCG levels <1000 IU/L respond well to treatment with intramuscular MTX.

    • tEPs with human chorionic gonadotrophin (hCG) levels >1000 IU/L require multiple hospital visits to resolve with MTX and often require surgery.

    • Novel combination therapy of MTX and the oral EGFR antagonist, gefitinib, could reduce the number of hospital visits required to resolve tEPs with hCG levels >1000 IU/L.

    Strengths and limitations of this study

    • This is a phase II exploratory efficacy trial, and will be the ‘first in man’ to examine the efficacy of gefitinib and MTX to treat tEPs with hCG levels >1000 IU/L

    • This is a ‘single arm’ trial. The data will be used to inform a future large multicentre randomised controlled trial comparing combination therapy to conventional management of tEPs.

    • The combination therapy described also has potential use in other pregnancy disorders where medical regression of placental tissue could be useful, for example, molar disease and regression of placenta accrete postpartum.

    Introduction

    Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in modern gynaecology in both the developed and developing world.1 ,2 tEPs with pretreatment serum human chorionic gonadotrophin (hCG) levels <1000 IU/L respond well to outpatient medical treatment with an intramuscular injection of methotrexate (MTX). Indeed, it has been suggested that these tEPs could be managed safely, and equally efficiently by expectant management without medical intervention.3–5 In contrast, single-dose MTX is only cost-effective in women with serum hCG concentrations <1500 IU/L.6 In tEPs with higher hCG levels (>60% of total tEPs), emergency laparoscopic surgical excision (with its inherent risks of damage to visceral organs) remains the most effective treatment. tEPs with higher hCG levels take a significant time to resolve with MTX and require multiple outpatient monitoring visits. There, therefore, exists a need for more effective medical treatments for tEPs with higher hCG levels to reduce the need for emergency surgery and reduce the time to resolution associated with MTX management.

    Gefitinib is an orally active epidermal growth factor receptor (EGFR) antagonist licensed to treat non-small-cell lung cancer.7 In preclinical studies, we found that EP implantation sites express high levels of EGFR and that gefitinib augments MTX-induced regression of pregnancy-like tissue.8 To translate this into clinical care, we performed a phase I single-arm open-label dose-escalation study administering a combination of 250 mg oral gefitinib (one dose (n=3), three daily doses (n=3), seven daily doses (n=6)) and intramuscular MTX (50 mg/m2) to 12 women with tEPs.9 The combination therapy did not cause any significant toxicities, and was well tolerated. We noted that resolution (fall in serum hCG to <15 IU/l) with combination therapy was faster than the median time for tEPs to resolve with MTX alone when compared with contemporaneous controls (21 vs 32 days).

    Objectives

    The objective of this trial is to evaluate the efficacy and side effects of combination gefitinib and MTX to treat tEPs (hCG 1000–10 000 IU/L).

    Methods and analysis

    Study design

    Phase II single-arm multicentre open label trial (Edinburgh and two sites in Melbourne).

    Subjects

    Twenty-eight women with tEPs with hCG levels 1000–10 000 IU/L.

    Study settings

    We intend to recruit patients from gynaecology departments within NHS Lothian (UK), and Southern Health and Mercy Health networks in Melbourne, Australia.

    Sample size

    We have calculated the sample size using A'Hern's formula for phase II one-stage designs.10 For treatment of tEPs with hCG levels 1000–10 000 IU/L by MTX /gefitinib to be considered effective, we expect a success rate of at least 90%.11 However, a success rate of 70% or less would be considered unacceptable. With 80% power and a 5% level of significance, 28 patients are required to enable us to assess whether the proportion of patients with a successful outcome to treatment is ≤70% or ≥90%. If 24, or more, patients have a successful outcome, we can reject the hypothesis that the true efficacy of MTX /gefitinib is ≤70% and progress to a phase III trial.

    Inclusion criteria

    Women aged between 18 and 45 years; pretreatment serum hCG of 1000–10 000 IU/L (rising or static); ultrasound diagnosis of definite tEP (extrauterine gestational sac with yolk sac and/or embryo, with or without cardiac activity) or probable tEP (inhomogeneous adnexal mass or extrauterine sac-like structure)12 performed by a clinical team of trained, qualified and experienced ultrasonographers; no clinical evidence of intra-abdominal bleeding; no pallor; no guarding/rigidity on abdominal examination; stable blood pressure and heart rate; haemoglobin on full blood examination at day 1 between 100 and 165 g/L).

    Exclusion criteria

    Women with a pregnancy of unknown location; evidence of a significant intra-abdominal bleed on ultrasound defined by free fluid above the uterine fundus or the surrounding ovary13; women with a history of any significant pulmonary disease; abnormal liver/renal/haematological indices; significant pre-existing dermatological conditions; significant pre-existing gastrointestinal medical illnesses; Japanese ethnicity.

    Participant enrolment

    All gynaecology consultants within NHS Lothian (UK), Southern Health and Mercy Health (both Australia) will be sent a letter informing them of the study and requesting permission to approach their patients. The clinical research team in NHS Lothian, Southern Health and Mercy Health will approach eligible women, provide them with patient information sheets and offer them the opportunity to discuss the trial, and obtain informed consent. Consent will only be taken once the patient has had ample time to read the patient information sheet and had her questions answered.

    Intervention

    Eligible women will be given a single-dose intramuscular MTX (50 mg/m2) injection with seven daily doses oral gefitinib (250 mg). The gefitinib will be started on the same date when the MTX injection is given.

    Data collection

    Data storage

    A log with the patients’ name and date of birth will be kept along with their unique study number in a separate file. All the data generated from the study will be stored in an anonymised form in a bespoke database, which will also be password protected. Only anonymised information will be stored on this, and participants will only be identifiable by their study number. All paperwork will be kept in a locked filing cabinet in a locked office. All data will be stored on university server (University of Edinburgh) on a password-protected computer with limited access to the research team, in accordance with the Data Protection Act (UK).

    Screening

    A member of the research team will carry out a screening visit to assess eligibility. All data will be recorded on a case record form and transferred to a secure database.

    Participant log

    The clinical research team will keep an electronic log of women who fulfil the eligibility criteria, women who are invited to participate in the study, women recruited and women who leave the trial early. Reasons for non-recruitment (eg, non-eligibility, refusal to participate, administrative error) will also be recorded. We will attempt to collect reasons for non-participation from women who decline to take part after previously providing contact details. During the course of the study, we will document reasons for withdrawal from the study and loss to follow-up (figure 1).

    Figure 1
    Figure 1

    Flow chart of participants involved in the study.

    Assessments

    To monitor treatment response, we will follow protocols used clinically for medical management with MTX. Serum hCG levels will be measured on days 4, 7 and 11, then weekly until hCG levels drop to non-pregnant levels (<15 IU/L). Medical management will be discontinued and patients will undergo surgery based on their response to MTX and clinical picture (eg, clinical evidence of intra-abdominal bleeding) following standard clinical paradigms documented by the assessing clinician. Participants will be contacted at 3 and 6 months post-treatment to document return of menstrual cycles and any subsequent pregnancies. To monitor safety and tolerability, women will be assessed clinically (history) and biochemically (haematological, renal and liver function tests) on days 4 and 7 (or if elevated, until return to normal physiological levels).

    Primary outcome

    Our primary outcome is resolution of tEP without requirement for surgery. Resolution is defined by serum hCG levels (the current clinical marker to monitor treatment response) falling to non-pregnant levels (hCG <15 IU/L). We have selected our primary outcome based on the data from our phase I trial where two patients recruited with pretreatment hCG levels >1000 IU/L required surgery and previously published data.14 We are using a cut-off of <15 IU/L, which corresponds to a negative urinary pregnancy test using the most sensitive assays.

    Secondary outcome

    1. Time to resolution (categorical variable) compared with historical controls of similar pretreatment serum hCG levels (identified by an individual blinded to the study).

    2. Safety and tolerability as determined by clinical and biochemical assessment. Both MTX and gefitinib have the potential to affect haematological, renal and liver function.

    Proposed analyses

    Given this is a single arm efficacy trial, the majority of the data will be expressed as descriptive statistics.

    Ethics and dissemination

    Ethical approval has been obtained from the Scotland A Research Ethics Committee (LREC 12/SS/0005) (UK), the Southern Health Human Research Ethics Committee B (SH HREC 11180B) and the Mercy Health Human Research Ethics Committee (R12/25) (both Australia). Data will be presented at international conferences and published in peer-reviewed journals. We will make the information obtained from the study available to the public through national bodies and charities (eg, Ectopic Pregnancy Trust).

    Adverse events

    Participants will collect information about adverse events in their treatment diaries. However, they will be instructed to contact the clinical research team at any time after consenting to join the trial if they have an event that requires hospitalisation or an event that results in persistent or significant disability or incapacity. Any serious adverse events that occur after joining the trial will be reported in detail in the participant’s medical notes, followed up until resolution of the event and reported to the ACCORD Research Governance (http://www.accord.ed.ac.uk) and QA Office based at the University of Edinburgh, or the Southern Health/Mercy Health Human Research Ethics Committees and Therapeutic Goods Administration of Australia's Office of Scientific Evaluation immediately or within 24–72 h.

    Discussion

    If effective, we believe that this combination (gefitinib and MTX) could become standard of care for stable tEPs. The combination also has potential use in other pregnancy disorders. There may be other important conditions where medical regression of pregnancy tissue could be useful, for example, women with complete molar pregnancies and persistent molar disease and women with placenta accrete postpartum (to avoid hysterectomy).

    Regarding the safety of gefitinib, data from post marketing surveillance representing over 92 000 patients exist and have shown that EGFR inhibitors are well tolerated and largely free of serious side effects (Food and Drug Administration (FDA) report).15 Of note, the data on tolerability are based on patients taking gefitinib daily on an ongoing, indefinite basis, after primary treatment of cancer. Diarrhoea and skin rash are the most common side effects (20–30%). The skin rash, described as acneiform, can be severe, but is generally self-limited. Skin rashes occur within a month of initiation of treatment, but rarely in the first week. Interstitial lung disease (ILD) is a very rare but a serious side effect of gefitinib. It is a thickening of the lung parenchyma that can be fatal in a third of cases. Of the 31 045 patients in the USA who took gefitinib (reported to the FDA), 84 developed ILD (0.3%). We plan to administer seven 250 mg gefitinib tablets, one daily for only 7 days, in addition to MTX. This is an extremely short duration of treatment compared with gefitinib's current marketing indications and existing data usage. We would not expect this short course to have an adverse long-term effect on fertility but we will be assessing participants 3 and 6 months posttreatment to document return of menstrual cycles and any subsequent pregnancies.

    We do not anticipate that this will be the final trial to determine whether further exploration of combination therapy with gefitinib and MTX is worthwhile. We hope that the study will generate sufficient ‘signal’ that gefitinib and MTX may be effective and safe, to support a funding application for a larger trial with a comparative group. Such a trial could be designed as an ‘equivalence’ trial in terms of treatment efficacy between conventional management and the gefitinib/MTX comparison. It would aim to test the hypothesis that gefitinib/MTX was superior in a range of outcomes prioritised by consumer groups and clinicians. We anticipate that these outcomes could include: time to resumption of normal activities, SF-36 at intervals after treatment and patient satisfaction scores. Outcomes of a subsequent pregnancy are also important but would require long-term follow-up studies. We anticipate that focus groups and surveys of patients and clinicians would be required to define the outcomes (other than efficacy) of these studies.

    References

    1. ↵
      1. Sivalingam VN,
      2. Duncan WC,
      3. Kirk E,
      4. et al
      . Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health Care 2011;37:231–40.
      OpenUrlFREE Full Text
    2. ↵
      1. Jurkovic D,
      2. Wilkinson H
      . Diagnosis and management of ectopic pregnancy. BMJ 2011;342:d3397.
      OpenUrlFREE Full Text
    3. ↵
      RCOG. The management of tubal pregnancy. Green top Guideline No 21, published in May 2004 (reviewed 2010). http://www.rcog.org.uk/files/rcog-corp/GTG21_230611.pdf
    4. ↵
      1. Mavrelos D,
      2. Nicks H,
      3. Jamil A,
      4. et al
      . Efficacy and safety of a clinical protocol for expectant management of selected women diagnosed with a tubal ectopic pregnancy. Ultrasound Obstet Gynecol 2013;42:102–7.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      1. Van Mello NM,
      2. Mol F,
      3. Verhoeve HR,
      4. et al
      . Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison. Hum Reprod 2013;28:60–7.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Mol F,
      2. Mol BW,
      3. Ankum WM,
      4. et al
      . Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 2008;14:309–19.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      1. Herbst RS,
      2. Fukvoka M,
      3. Baselga J
      . Gefitinib – a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956–65.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      1. Nilsson UW,
      2. Johns TG,
      3. Wilmann T,
      4. et al
      . Effects of Gefinitb, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth. Obstet Gynecol. In press.
    9. ↵
      1. Skubisz MM,
      2. Horne AW,
      3. Johns TG,
      4. et al
      . Combination Gefitinib and Methotrexate Compared with Methotrexate Alone to Treat Ectopic Pregnancy. Obstet Gynecol. In press.
    10. ↵
      1. A'Hern RP
      . Sample size tables for exact single stage Phase II designs. Stat Med 2001;20:859–866.
      OpenUrlCrossRefPubMedWeb of Science
      1. Menon S,
      2. Colins J,
      3. Barnhart KT
      . Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007;87:481–4.
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      1. Barnhart K,
      2. Van Mello NM,
      3. Bourne T,
      4. et al
      . Pregnancy of unknown location: a consensus statement of nomenclature, definitions, and outcome. Fertil Steril 2011;95:857–66.
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Fauconnier A,
      2. Mabrouk A,
      3. Salomon LJ,
      4. et al
      . Ultrasound assessment of haemoperitoneum in ectopic pregnancy: derivation of a prediction model. World J Emerg Surg 2007;2:23.
      OpenUrlPubMed
    14. ↵
      1. Menon S,
      2. Colins J,
      3. Barnhart KT
      . Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007;87:481–4.
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      1. Cohen MH,
      2. Williams GA,
      3. Sridhara R,
      4. et al
      . United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212–18.
      OpenUrlAbstract/FREE Full Text

    Footnotes

    • Contributors AH and ST were involved in research, contribution of original material, editing and approval of final manuscript; AD and MS were also involved in contribution of original material, editing and approval of final manuscript; MS, MR, CD, EW, HC, TJ, SB, JM and JN edited and approved the final manuscript.

    • Funding This work is supported by an NHMRC Grant (#1008276) to ST, TJ and EW, and an MRC Centenary Award (G0802808) to AH. The funders will have no role in the study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit the report for publication.

    • Competing interests AH is funded by an MRC Clinician Scientist Fellowship and MRC Centenary Award (G0802808) and holds grants from the Chief Scientist’s Office Scotland (CZH/4/688) (HC coinvestigator) and Well-being of Women. HC holds an MRC DCS Grant (G003611), an MRC Centre Grant (G1002033) and research collaboration funding from Bayer Pharma AG. UN, TJ and ST are joint holders of patents that relate to the use of EGFR inhibition in treating ectopic pregnancies.

    • Ethics approval Ethical approval has been obtained from Scotland A Research Ethics Committee (MREC 11/AL/0350), Southern Health Human Research Ethics Committee B (HREC 11180B) and the Mercy Health Human Research Ethics Committee (R12/25).

    • Provenance and peer review Not commissioned; externally peer reviewed.